GALVmed has entered into a new agreement with the University of Toronto, and Engineered Antigens Inc, a spinoff company by University of Calgary and University of Toronto, as well as […]
Stakeholders meet in Nairobi to expand access to affordable livestock disease testing Nairobi, Kenya, 01 April 2026: Livestock diseases continue to pose a significant threat to farmers’ livelihoods, food security […]
We’re excited to share GALVmed’s 2025 Year in Review, an overview of our accomplishments and the progress made throughout the year in advancing our mission. The review reflects a year […]
Small-scale livestock producers across sub-Saharan Africa continue to operate in an increasingly complex environment. Disease pressures remain high, climate variability is intensifying risk, and public animal health systems are often […]
Nairobi, Kenya, 20th November 2025. The African Union Commission, through the African Union Inter-African Bureau for Animal Resources (AU-IBAR) and the African Union Pan African Veterinary Vaccine Centre (AU-PANVAC), with […]
GALVmed has officially launched its new 5-year programme, Veterinary Innovations Transforming Animal health & Livelihoods (VITAL 2) in Nigeria and Kenya. The new programme will leverage public and private partnerships […]
On 15th October 2025, as part of the Food and Agriculture Organization’s (FAO) 80th anniversary celebrations and on the occasion of the World Food Forum, the AgResults Foot and Mouth […]
At the recently held FAO 2025 Global Conference on Sustainable Livestock transformation, GALVmed participated in a side event titled “Tackling Tick and Acaricide Resistance through Surveillance and Diagnostics – From local […]
Dr Lois Muraguri, GALVmed’s first African CEO, calls for systemic change to deliver sustainable animal health solutions to small-scale livestock producers in low- and middle-income countries. October 1, 2025, Edinburgh, […]
The Pirbright Institute, through the Centre for Veterinary Vaccine Innovation and Manufacturing (CVIM), has entered into a new agreement with GALVmed to develop and deploy a safer and more effective […]
